Back to mobile site

More on BLTE

- Summary
- Chart
- Profile
- Historical

Data

- Earnings (-141.9% Growth)
- Ratings (10.0 Score)
- Holders

Upcoming Events

- Earnings (8/12/26)

News

- Analyst Ratings
- Earnings Related
- Guidance
- Insider Trades
- Mgmt Changes
- M & A
- Retail Sales
- Rumors
- Stock Buybacks
More...

Belite Bio (NQ:BLTE)
Delayed: 149.33 -3.91 (2.55%)
Prev. Close $153.24  
Open$152.50 
52 Wk High$ 
52 Wk Low$ 
Day High$154.25 
Day Low$145.57 
P/E N/A  
EPS$ 
Volume153,710 

Friends, Peers and Foes (?): VIOT, YRD, IH, LOT, COE (more...)

Jul 6, 2026 08:00 AM Belite Bio to Participate in the Piper Sandler Virtual Ophthalmology Investor Symposium
Jul 6, 2026 07:00 AM Belite Bio Announces Oral Presentations at Two Upcoming Medical Conferences
Jun 22, 2026 06:06 AM Form 4 BELITE BIO, INC For: Jun 18 Filed by: Scholl Hendrik Peter
Jun 18, 2026 04:27 PM Form 144 BELITE BIO, INC Filed by: Scholl Hendrik Peter
Jun 17, 2026 06:04 AM Form 4 BELITE BIO, INC For: Jun 16 Filed by: Scholl Hendrik Peter
Jun 16, 2026 07:11 PM Form 144 BELITE BIO, INC Filed by: Scholl Hendrik Peter
Jun 16, 2026 06:44 AM H.C. Wainwright Reiterates Buy Rating on Belite Bio, Inc, ADR (BLTE)
Jun 15, 2026 06:15 AM Form 6-K BELITE BIO, INC For: Jun 12
Jun 15, 2026 03:02 AM Belite Bio completes FDA drug application for rare eye disease treatment
Jun 12, 2026 09:30 PM Belite Bio Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease Type 1
View All Articles

Entities mentioned with BLTE

View All Entities